AP4036A - Transdermal delivery system comprising buprenorphine - Google Patents

Transdermal delivery system comprising buprenorphine

Info

Publication number
AP4036A
AP4036A AP2014007779A AP2014007779A AP4036A AP 4036 A AP4036 A AP 4036A AP 2014007779 A AP2014007779 A AP 2014007779A AP 2014007779 A AP2014007779 A AP 2014007779A AP 4036 A AP4036 A AP 4036A
Authority
AP
ARIPO
Prior art keywords
buprenorphine
delivery system
transdermal delivery
transdermal
delivery
Prior art date
Application number
AP2014007779A
Other languages
English (en)
Other versions
AP2014007779A0 (en
Inventor
Thomas Hille
Gabriel Wauer
Kevin John Smith
Gillian Elizabeth Mundin
Helen Elizabeth Johnson
Original Assignee
Lohmann Therapie Syst Lts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47754872&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP4036(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lohmann Therapie Syst Lts filed Critical Lohmann Therapie Syst Lts
Publication of AP2014007779A0 publication Critical patent/AP2014007779A0/xx
Application granted granted Critical
Publication of AP4036A publication Critical patent/AP4036A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AP2014007779A 2011-12-12 2012-12-12 Transdermal delivery system comprising buprenorphine AP4036A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161569609P 2011-12-12 2011-12-12
PCT/IB2012/002973 WO2013088254A1 (en) 2011-12-12 2012-12-12 Transdermal delivery system comprising buprenorphine

Publications (2)

Publication Number Publication Date
AP2014007779A0 AP2014007779A0 (en) 2014-07-31
AP4036A true AP4036A (en) 2017-02-22

Family

ID=47754872

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2014007779A AP4036A (en) 2011-12-12 2012-12-12 Transdermal delivery system comprising buprenorphine

Country Status (26)

Country Link
US (4) US20140363487A1 (enExample)
EP (1) EP2790685B2 (enExample)
JP (2) JP6289378B2 (enExample)
KR (1) KR102014565B1 (enExample)
CN (2) CN104114161A (enExample)
AP (1) AP4036A (enExample)
AR (1) AR089201A1 (enExample)
AU (1) AU2012327247B2 (enExample)
BR (1) BR112014014137A2 (enExample)
CA (1) CA2858531C (enExample)
CL (1) CL2014001559A1 (enExample)
CO (1) CO7000779A2 (enExample)
CR (1) CR20140321A (enExample)
DE (1) DE112012005185T5 (enExample)
EA (1) EA201491164A1 (enExample)
ES (1) ES2647516T3 (enExample)
GB (1) GB2512007B8 (enExample)
IL (1) IL233025A0 (enExample)
MX (1) MX352795B (enExample)
PE (1) PE20142341A1 (enExample)
PH (1) PH12014501231A1 (enExample)
PL (1) PL2790685T3 (enExample)
SG (2) SG11201403162XA (enExample)
TN (1) TN2014000233A1 (enExample)
TW (1) TW201338813A (enExample)
WO (1) WO2013088254A1 (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
DE102006054731B4 (de) 2006-11-21 2013-02-28 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie
BRPI0811319A2 (pt) 2007-05-25 2015-02-10 Tolmar Therapeutics Inc Composição fluida, método de formação de uma composição fluida, implante biodegrádavel formado in situ, método de formação de um implante biodegradável in situ, kit, implante e método de trataento
GB2481017B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
US20130017259A1 (en) 2011-07-06 2013-01-17 The Parkinson's Institute Compositions and Methods for Treatment of Symptoms in Parkinson's Disease Patients
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
RS62297B1 (sr) 2011-11-23 2021-09-30 Therapeuticsmd Inc Prirodne kombinovane hormonske supstitucione formulacije i terapije
CA2856196C (en) 2011-12-06 2020-09-01 Masco Corporation Of Indiana Ozone distribution in a faucet
TW201338813A (zh) * 2011-12-12 2013-10-01 洛曼治療系統股份有限公司 經皮遞送系統
US9566241B2 (en) 2012-02-21 2017-02-14 Auburn University Buprenorphine nanoparticle composition and methods thereof
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
BR112015029920A2 (pt) * 2013-06-04 2017-07-25 Lts Lohmann Therapie Systeme Ag sistema de administração transdérmica
CA2916183C (en) 2013-07-03 2022-03-29 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system with electronic component
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
JP6895755B2 (ja) 2014-05-20 2021-06-30 エルテーエス ローマン テラピー−ジステーメ アーゲー 経皮送達システムにおける活性薬剤の放出を調節するための方法
EP4238580A3 (en) 2014-05-20 2023-10-25 LTS Lohmann Therapie-Systeme AG Transdermal delivery system including an interface mediator
JP6573913B2 (ja) 2014-05-20 2019-09-11 エルテーエス ローマン テラピー−ジステーメ アーゲー ロチゴチンを含む経皮送達システム
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
WO2016123406A1 (en) 2015-01-28 2016-08-04 Chrono Therapeutics Inc. Drug delivery methods and systems
CN107660207B (zh) 2015-03-10 2020-09-29 罗德科技公司 丁丙诺啡乙酸盐及用于制备丁丙诺啡的方法
EP3267875A4 (en) 2015-03-12 2018-12-05 Chrono Therapeutics Inc. Craving input and support system
EP3067050A1 (en) 2015-03-13 2016-09-14 Acino AG Transdermal therapeutic system with an overtape comprising two adhesive layers
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017048595A1 (en) * 2015-09-14 2017-03-23 Amneal Pharmaceuticals Llc Transdermal delivery system
CN115093008B (zh) 2015-12-21 2024-05-14 德尔塔阀门公司 包括消毒装置的流体输送系统
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
WO2018129304A1 (en) 2017-01-06 2018-07-12 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
WO2019064026A1 (en) 2017-09-29 2019-04-04 Orexo Ab NEW PHARMACEUTICAL COMPOSITIONS
GB201716830D0 (en) 2017-10-13 2017-11-29 Cambrex Charles City Inc New Process
BR112020018607A2 (pt) 2018-03-13 2020-12-29 Lts Lohmann Therapie-Systeme Ag Sistema terapêutico transdérmico compreendendo um polímero híbrido de silicone acrílico
CA3092757A1 (en) 2018-03-13 2019-09-19 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system comprising a silicone acrylic hybrid polymer
BR112020018290A2 (pt) 2018-03-13 2020-12-29 Lts Lohmann Therapie-Systeme Ag Sistema terapêutico transdérmico compreendendo um polímero híbrido de silicone e acrílico
CA3101966A1 (en) 2018-05-29 2019-12-05 Morningside Venture Investments Limited Drug delivery methods and systems
US12397141B2 (en) 2018-11-16 2025-08-26 Morningside Venture Investments Limited Thermally regulated transdermal drug delivery system
GB201904767D0 (en) 2019-04-04 2019-05-22 Orexo Ab New pharmaceutical compositions
CN113952319A (zh) * 2021-11-30 2022-01-21 烟台大学 一种含丁丙诺啡的骨架型透皮贴剂及其制备方法
CN114397411A (zh) * 2021-12-14 2022-04-26 苏州高迈药业有限公司 一种评价利丙双卡因乳膏的方法
WO2024040897A1 (zh) * 2022-08-24 2024-02-29 新领医药技术(深圳)有限公司 沙利度胺或其类似物透皮贴剂及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996019975A1 (de) * 1994-12-24 1996-07-04 Lts Lohmann Therapie-Systeme Gmbh Transdermale resorption von wirkstoffen aus unterkühlten schmelzen
WO2004001436A2 (en) * 2002-06-20 2003-12-31 Baker Hughes Incorporated Antenna core material for use in mwd resistivity measurements an d nmr measurements
US20100119585A1 (en) * 2006-11-21 2010-05-13 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system for administering the active substance buprenorphine

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US119585A (en) * 1871-10-03 Improvement in horse-collars and hames
US3474101A (en) 1960-09-05 1969-10-21 Reckitt & Sons Ltd Thebaine and oripavine derivatives
GB1136214A (en) 1965-06-15 1968-12-11 Reckitt & Sons Ltd Thebaine and oripavine derivatives
US4806341A (en) 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
CA2002299A1 (en) 1988-11-10 1990-05-10 Eugene G. Drust Compositions for the transdermal delivery of buprenorphine salts
DE3939376C1 (enExample) 1989-11-29 1991-05-08 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg, 5450 Neuwied, De
US5240711A (en) † 1989-11-29 1993-08-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system comprising as active component buprenorphine
US5069909A (en) † 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine
US5635203A (en) * 1994-09-29 1997-06-03 Alza Corporation Transdermal device having decreased delamination
US5968547A (en) * 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
DE19922662C1 (de) 1999-05-18 2000-12-28 Sanol Arznei Schwarz Gmbh Transdermales therapeutisches System (TTS) Tolterodin enthaltend
CA2374930C (en) 1999-07-02 2008-08-05 Lts Lohmann Therapie-Systeme Ag Microreservoir system based on polysiloxanes and ambiphilic solvents
DE19958554C2 (de) 1999-07-02 2002-06-13 Lohmann Therapie Syst Lts Mikroreservoirsystem auf Basis von Polysiloxanen und ambiphilen Lösemitteln und ihre Herstellung
WO2001014336A1 (en) * 1999-08-20 2001-03-01 Nippon Kayaku Kabushiki Kaisha Benzene derivatives substituted by aromatic ring and process for producing the same
AU776666B2 (en) 2000-02-08 2004-09-16 Euro-Celtique S.A. Tamper-resistant oral opioid agonist formulations
JP4659943B2 (ja) * 2000-02-25 2011-03-30 帝三製薬株式会社 塩酸ブプレノルフィン含有貼付剤
US6682757B1 (en) 2000-11-16 2004-01-27 Euro-Celtique, S.A. Titratable dosage transdermal delivery system
JP2004525960A (ja) * 2001-02-16 2004-08-26 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 尿失禁、特に切迫尿失禁の治療用経皮デリバリーディバイスの製造にブプレノルフィンを使用する方法
DE10141651B4 (de) 2001-08-24 2007-02-15 Lts Lohmann Therapie-Systeme Ag Transdermales Therapeutisches System (TTS) mit dem Wirkstoff Fentanyl und Verfahren zu seiner Herstellung
US20050118245A1 (en) 2002-03-27 2005-06-02 Wilsmann Klaus M. Assembled unit consisting of individually separable, transdermal, therapeutic systems
DE10213772A1 (de) 2002-03-27 2003-10-09 Gruenenthal Gmbh Zusammenhängende Einheit aus vereinzelbaren transdermalen therapeutischen Systemen
ATE367155T1 (de) * 2002-08-09 2007-08-15 Gruenenthal Gmbh Opiod-rezeptor-antagonisten in transdermalen systemen mit buprenorphin
US20050191340A1 (en) * 2002-08-09 2005-09-01 Gruenenthal Gmbh Opioid-receptor antagonists in transdermal systems having buprenorphine
WO2004054553A1 (en) * 2002-12-13 2004-07-01 Euro-Celtique S.A. Transdermal buprenorphine dosage regimen for analgesia
RU2324372C2 (ru) 2003-03-25 2008-05-20 Моринда, Инк. Селективное ингибирование продукции эстрогена и обеспечение эстрогенного действия в организме человека
US8790689B2 (en) * 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
US7182955B2 (en) * 2003-04-30 2007-02-27 3M Innovative Properties Company Abuse-resistant transdermal dosage form
DE102004045599A1 (de) 2004-09-17 2006-03-23 Grünenthal GmbH System zur sequentiellen, transdermalen Verabreichung von systemisch wirksamen Substanzen
DE102004062647A1 (de) 2004-12-21 2006-06-29 Kronotec Ag Holzfaserdämmstoffplatte bzw.- matte
DE102004062614B4 (de) 2004-12-24 2011-12-29 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit aktivierbarer Übersättigung und kontrollierter Permeationförderung sowie Verfahren zu dessen Herstellung
DE102006054732B4 (de) † 2006-11-21 2010-12-30 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit Ionenpaar-Mikroreservoiren
EP2366388A1 (de) 2010-03-17 2011-09-21 Ratiopharm GmbH Nicht-okklusives transdermales therapeutisches System zur Verabreichung von Buprenorphin
TW201338813A (zh) 2011-12-12 2013-10-01 洛曼治療系統股份有限公司 經皮遞送系統
AU2013205080B2 (en) 2012-12-12 2016-07-07 Lts Lohmann Therapie-Systeme Ag Transdermal Delivery System
BR112015029920A2 (pt) 2013-06-04 2017-07-25 Lts Lohmann Therapie Systeme Ag sistema de administração transdérmica

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996019975A1 (de) * 1994-12-24 1996-07-04 Lts Lohmann Therapie-Systeme Gmbh Transdermale resorption von wirkstoffen aus unterkühlten schmelzen
WO2004001436A2 (en) * 2002-06-20 2003-12-31 Baker Hughes Incorporated Antenna core material for use in mwd resistivity measurements an d nmr measurements
US20100119585A1 (en) * 2006-11-21 2010-05-13 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system for administering the active substance buprenorphine

Also Published As

Publication number Publication date
JP2017036304A (ja) 2017-02-16
US20140363487A1 (en) 2014-12-11
EP2790685A1 (en) 2014-10-22
US20160120823A1 (en) 2016-05-05
NZ626535A (en) 2017-02-24
CR20140321A (es) 2014-11-13
IL233025A0 (en) 2014-07-31
GB201412385D0 (en) 2014-08-27
TW201338813A (zh) 2013-10-01
CA2858531C (en) 2019-12-17
MX352795B (es) 2017-12-07
EP2790685B1 (en) 2017-08-16
US20200306204A1 (en) 2020-10-01
JP2015500329A (ja) 2015-01-05
BR112014014137A8 (pt) 2017-06-13
EA201491164A1 (ru) 2014-10-30
GB2512007B8 (en) 2017-06-28
GB2512007B (en) 2017-04-26
DE112012005185T5 (de) 2014-08-28
KR20140101858A (ko) 2014-08-20
US20170049713A1 (en) 2017-02-23
JP6289378B2 (ja) 2018-03-07
CN104114161A (zh) 2014-10-22
PE20142341A1 (es) 2015-01-17
CA2858531A1 (en) 2013-06-20
SG11201403162XA (en) 2014-10-30
AP2014007779A0 (en) 2014-07-31
AR089201A1 (es) 2014-08-06
GB2512007A (en) 2014-09-17
CO7000779A2 (es) 2014-07-21
PH12014501231A1 (en) 2014-09-08
BR112014014137A2 (pt) 2017-06-13
EP2790685B2 (en) 2026-04-01
AU2012327247A1 (en) 2013-06-27
US9549903B2 (en) 2017-01-24
TN2014000233A1 (en) 2015-09-30
ES2647516T3 (es) 2017-12-22
HK1203048A1 (en) 2015-10-16
KR102014565B1 (ko) 2019-08-26
CN107669662A (zh) 2018-02-09
HK1201760A1 (en) 2015-09-11
MX2014007020A (es) 2014-07-14
SG10201604754VA (en) 2016-08-30
WO2013088254A1 (en) 2013-06-20
CL2014001559A1 (es) 2014-10-03
GB2512007A8 (en) 2017-06-28
PL2790685T3 (pl) 2018-04-30
AU2012327247B2 (en) 2015-12-24

Similar Documents

Publication Publication Date Title
IL233025A0 (en) Transdermal delivery system containing buprenorphine
EP2683328A4 (en) RELEASE SYSTEM
GB201121069D0 (en) Delivery system
ZA201400611B (en) Shelf-monitoring system
HUE068153T2 (hu) Biztonságos szekvenálási rendszer
GB201105902D0 (en) Location system
ZA201305933B (en) Auto-injector
ZA201504964B (en) Transdermal delivery system
EP2719500A4 (en) PART PROCESSING SYSTEM
PH12013502174A1 (en) Vaccine delivery method
ZA201309156B (en) Drug delivery system
GB2500948B (en) Ablutionary system
ZA201401657B (en) Pimping system
SG10201609440WA (en) Multi-additive delivery system
PL2741811T3 (pl) Układ do leczenia objawów
ZA201405249B (en) Transdermal hormone delivery
SG11201405743QA (en) Liposomal delivery system
EP2700820A4 (en) ENGINE ATTACHMENT SYSTEM
GB201112636D0 (en) Delivery system and method
ZA201200932B (en) Protection system
HK1201760B (en) Transdermal delivery system
GB201108399D0 (en) Secure delivery system
GB201214708D0 (en) Secure delivery system
AU2011904002A0 (en) Secure Delivery System
GB201107503D0 (en) Delivery device